Omarigliptin
Omarigliptin (MK-3102) is a Dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) drug used in the treatment of Type 2 diabetes. It was developed by Merck & Co. and approved in Japan in 2015. However, it has not been approved for use in the United States or Europe.
Mechanism of Action
Omarigliptin works by inhibiting the enzyme Dipeptidyl peptidase-4 (DPP-4). This enzyme is involved in the breakdown of Incretin hormones, which are responsible for increasing the amount of insulin released by the pancreas. By inhibiting DPP-4, Omarigliptin increases the levels of incretin hormones, leading to increased insulin release and decreased glucose levels in the blood.
Clinical Trials
Omarigliptin has undergone several clinical trials to assess its safety and efficacy in treating Type 2 diabetes. In a Phase III trial conducted in Japan, Omarigliptin was found to be effective in reducing HbA1c levels in patients with Type 2 diabetes.
Approval
Omarigliptin was approved for use in Japan in September 2015. However, in 2016, Merck & Co. announced that they would not seek approval for Omarigliptin in the United States or Europe, citing a desire to focus on other drugs in their portfolio.
Side Effects
Common side effects of Omarigliptin include Nausea, Headache, and Upper respiratory tract infection. In rare cases, it can cause Pancreatitis and Hypoglycemia.
See Also
 | This medical article is a stub. You can help WikiMD by expanding the page. |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
